Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer
Crossref DOI link: https://doi.org/10.1007/s10549-014-3042-3
Published Online: 2014-07-11
Published Print: 2014-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Diaby, Vakaramoko
Adunlin, Georges
Zeichner, Simon B.
Avancha, Kiran
Lopes, Gilberto
Gluck, Stefan
Montero, Alberto J.
Text and Data Mining valid from 2014-07-11